|

Tirzepatide Clinical Trials

26 actively recruiting trials across 14 locations

Also known as: GIP/GLP-1RA, LY3298176, LY3298176 (development code name), Mounjaro, Mounjaro (brand name in certain regions), Spartina, Tirzepatide 5、10、15mg, ZepBound, Zepbound, Zepbound (brand name in certain regions), Zepbound, LY3298176

Other11 trials

San Antonio, Texas2 trials

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

University of Texas Health Science Center at San Antonio

Phase 2

Tuscaloosa, Alabama1 trial

Avondale, Arizona1 trial

Duarte, California1 trial

Tarzana, California1 trial

Torrance, California1 trial

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)

Phase 4

Miami, Florida1 trial

Honolulu, Hawaii1 trial

Boston, Massachusetts1 trial

Basking Ridge, New Jersey1 trial

Elizabeth, New Jersey1 trial

Cleveland, Ohio1 trial

Dallas, Texas1 trial

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center

Phase 2

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.